BGI Genomics overhauls governance, forecasts FX hedging, reports Q3 results

BGI Genomics' board of directors has approved a comprehensive overhaul of its corporate governance, including the revision and adoption of 30 governance documents. Key changes include the abolition of the supervisory board, with its functions now transferred to the board's audit committee. The company's registered capital increased from CNY 415,821,575 to CNY 418,317,075 due to share incentives. These changes are designed to strengthen governance, improve operational efficiency, and mitigate risks, reflecting adherence to updated regulatory requirements.

In financial news, BGI Genomics projects foreign exchange hedging operations for 2026, anticipating a maximum contract value of CNY 1 billion. This strategy aims to mitigate currency fluctuation risks, particularly given the CNY 18,759.19 million in credit impairment losses and CNY 889.93 million in asset impairment losses reported for the first nine months of 2025. The company also reported a Q3 2025 revenue of CNY 1,042,166,389.29 and a net loss attributable to shareholders of CNY 27,165,209.53, with a cumulative nine-month revenue of CNY 2,673,638,742.11 and a net loss of CNY 21,386,988.41.

Additionally, the company will increase its 2025 daily related party transaction forecast by CNY 83.42 million, primarily for procurement and sales. BGI Genomics also announced a joint technology project with related parties, valued at CNY 120 million, to develop pathogen sequencing systems, with a self-funded portion of CNY 100 million.